Anti-Angiogenic Therapies in the Management of Glioblastoma

Jessica D. Schulte; Manish K. Aghi; Jennie W. Taylor

Disclosures

Chin Clin Oncol. 2021;10(4):37 

In This Article

Conclusions

Angiogenesis is a hallmark feature of GBM and the role of anti-angiogenic agents in GBM treatment has evolved over time. While initial trials were promising that these agents could impact prognosis, many agents including anti-VEGF antibody failed to prolong survival in both newly diagnosed and recurrent GBM, either as monotherapy or in combination with traditional chemotherapies and other targeted agents. Despite these challenges, anti-angiogenic agents still have utility for managing vasogenic and radiation-related edema, being used in combination to target multiple angiogenic pathways, and to promote the intratumoral uptake of other chemotherapies.

processing....